97802-53-4
97802-53-4
Chemical Structure
Hexadecenyl-2-hydroxy-sn-glycero-3-PC
Synonym(s): C16(Plasm) LPC; Lysophosphatidylcholine 16:0p/0:0
- CAS No.: 97802-53-4
- Formula:C24H50NO6P
- Molecular Weight:479.63
InChIKey: HTZINLFNXLXRBC-CQLBIITFSA-N
SMILES: CCCCCCCCCCCCCC/C=C\OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O
Biological Activity: Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Hexadecenyl-2-hydroxy-sn-glycero-3-PC | 99.79% | Hexadecenyl-2-hydroxy-sn-glycero-3-PC (C16(Plasm) LPC) is a phosphatidylcholine. Hexadecenyl-2-hydroxy-sn-glycero-3-PC prolongs the lag-phase of α-syn aggregation, and can be used in Parkinson’s disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LysoPC(14:0/0:0) | 99.84% | LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
1-Palmitoyl-sn-glycero-3-phosphocholine | 99.92% | 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lyso-PAF C-16 | 99.87% | Lyso-PAF C-16 is a precursor and metabolite of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (PAF C-16). Lyso-PAF C-16 is a substrate for either PAF C-16 formation by the remodeling pathway or selective acylation with arachidonic acid by a CoA-independent transacylase. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lyso-PAF C-18 | 99.74% | Lyso-PAF C-18 is a single-chain ether phospholipid with membrane regulatory activity, and Lyso-PAF is the deacetylated inactive precursor of PAF. Lyso-PAF C-18 regulates the activity of plasma membrane Ca2+-ATPase, and its mechanism of action may involve altering the lipid microenvironment of this enzyme. Lyso-PAF C-18 activates the calcium ATPase in rat synaptosomal membranes and inhibits the calcium ATPase in rat leukocyte membranes. Lyso-PAF C-18 can be used in cell membrane-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18(Plasm) LPE | 99.0% | C18(Plasm) LPE (PE(18:1p/0:0)) is a bioactive lipid with the activity of regulating cell signaling and promoting cell growth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18:1 Lyso PAF | C18:1 Lyso PAF is a kind of biochemical reagent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C17 Lyso PAF | C17 Lyso PAF (1-O-Heptadecyl-2-hydroxy-sn-glycero-3-phosphocholine) is a precursor and metabolite of 1-O-heptadecyl-2-acetyl-sn-glycero-3-phosphocholine (C17:0 PAF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LysoPE(P-16:0/0:0) | LysoPE(P-16:0/0:0) is an endogenous lysophosphatidylethanolamine phospholipid metabolite that can serve as a biomarker for research on rheumatoid arthritis, Mycobacterium tuberculosis infection, and cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18(Plasm) LPC | 99.0% | C18(Plasm) LPC (PC(18:1p/0:0)) is classified as a type of plasmalogen. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
15:0 Lyso PC | 99.6% | 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
